CXCL1 and type 2 diabetes mellitus: To identify possible molecular mechanisms for the dose-dependency of the T2D-AT angiogenic response to GROα, T2D-AT explants were treated with [ND-GROα] and [T2D-GROα] for 4d and the levels of MMP-2 and MMP-9 released into the media measured.